Document is current
Any future updates will be listed below
-
Authors
Shea, Moira
Hill, Emma
Roland-Mcgowan, Jaclyn
Becker, Sarah L.
Simpson, Eric
- License Information
-
More Information
Article History
Received: 4 December 2024
Revised: 9 December 2024
Accepted: 3 January 2025
First Online: 10 January 2025
Declarations
:
: Authors Emma Hill, MD, Moira Shea, BS, Jaclyn Roland-Mcgowan, BS, and Sarah L Becker, BA have no conflicts of interest to report. Dr. Eric Simpson reports personal fees from AbbVie, Amgen, Arcutis, Areteia Therapeutics,, Bristol Myers Squibb – BMS, CorEvitas, Corvus, Dermira, Eli Lilly, Evelo Biosciences, FIDE, Forte Bio RX, Galderma, GlaxoSmithKline, Gilead Sciences, Impetus Healthcare, Incyte, Innovaderm Reche, Janssen, Johnson & Johnson, Kyowa Kirin Pharmaceutical Development, Leo, Merck, MJH holding (4/29/2021), NUMAB Therapeutics AG, Pfizer, Physicians World LLC, PRImE, Recludix Pharma, Regeneron, Roivant, Sanofi-Genzyme, Trevi therapeutics, Valeant. Dr. Eric Simpson reports grants (or serves as Principal investigator role) for AbbVie, Acrotech, Amgen, Arcutis, ASLAN, Castle, CorEvitas, Dermavant, Dermira, Incyte, Lilly, Kymab, Kyowa Kirin, National Jewish Health, Leo, Pfizer, Regeneron, Sanofi, Target, VeriSkin.
: This study received approval by Oregon Health & Science University’s Institutional Review Board, Study #25367.
: Not applicable—IRB approved HIPAA waiver obtained (#25367).
